ERYTHROMYCIN- erythromycin ointment

Country: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

Erythromycin (UNII: 63937KV33D) (Erythromycin - UNII:63937KV33D)

Disponibbli minn:

Cardinal Health

INN (Isem Internazzjonali):

Erythromycin

Kompożizzjoni:

Erythromycin 5 mg in 1 g

Rotta amministrattiva:

OPHTHALMIC

Tip ta 'preskrizzjoni:

PRESCRIPTION DRUG

Indikazzjonijiet terapewtiċi:

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Sommarju tal-prodott:

Sterile Erythromycin Ophthalmic Ointment USP, 0.5% is available as follows: Overbagged with 5 x 3.5 g (1/8 oz) sterile tamper-resistant tubes, NDC 55154-1276-5 STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing. Akorn Manufactured by: Akorn Inc Lake Forest, IL 60045 ERT00N Rev. 05/10 Distributed by: Cardinal Health Dublin, OH 43017 L43673480218

L-istatus ta 'awtorizzazzjoni:

Abbreviated New Drug Application

Karatteristiċi tal-prodott

ERYTHROMYCIN- ERYTHROMYCIN OINTMENT
CARDINAL HEALTH
----------
ERYTHROMYCIN OPHTHALMIC OINTMENT USP, 0.5%
STERILE
RX ONLY
DESCRIPTION:
Erythromycin Ophthalmic Ointment belongs to the macrolide group of
antibiotics. It is basic and readily
forms a salt when combined with an acid. The base, as crystals or
powder, is slightly soluble in water,
moderately soluble in ether, and readily soluble in alcohol or
chloroform. Erythromycin ((3R*, 4S*,
5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*,
14R*)-4-[(2,6-dideoxy-3-C-methyl-3-_O_-methyl-α-L-_ribo_-
hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-
(dimethyl-amino)-β-D-_xylo_-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione))
is an antibiotic
produced from a strain of _Streptomyces erythraeus._
It has the following structural formula:
Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base
of mineral oil and white
petrolatum.
CLINICAL PHARMACOLOGY:
_MICROBIOLOGY:_ Erythromycin inhibits protein synthesis without
affecting nucleic acid synthesis.
Erythromycin is usually active against the following organisms _in
vitro_ and in clinical infections:
_Streptococcus pyogenes_ (group A β-hemolytic)
Alpha-hemolytic streptococci (viridans group)
_Staphylococcus aureus_, including penicillinase-producing strains
(methicillin-resistant staphylococci are
uniformly resistant to erythromycin)
_Streptococcus pneumoniae_
_Mycoplasma pneumoniae_ (Eaton Agent, PPLO)
_Haemophilus influenzae_ (not all strains of this organism are
susceptible at the erythromycin
concentrations ordinarily achieved)
_Treponema pallidum_
_Corynebacterium diphtheriae_
_Neisseria gonorrhoeae_
_Chlamydia trachomatis_
INDICATIONS AND USAGE:
For the treatment of superficial ocular infections involving the
conjunctiva and/or cornea caused by
organisms susceptible to erythromycin.
For prophylaxis of ophthalmia neonatorum due to _N. gonorrhoeae_ or
_C. trachomatis_.
The effectiveness of erythromycin in the prevention of ophthalmia
caused by penicillinase-producing
_N.